About: Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Creator	Zheng, Wei Chen, Lu Muratov, Eugene Guo, Hui Shinn, Paul Simeonov, Anton Hall, Matthew Chen, Catherine Eastman, Richard Itkin, Zina Michael, Sam Bobrowski, Tesia Hall, Beard Zakharov, Alexey
source	BioRxiv; Medline; PMC
abstract	COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1101/2020.06.29.178889
bibo:pmid	32637956
has license	cc-by-nc-nd
sha1sum (hex)	31326d15d90a07cbd66724dfb0b66120bc04a820
schema:url	https://doi.org/10.1101/2020.06.29.178889
resource representing a document's title	Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
has PubMed Central identifier	PMC7337386
has PubMed identifier	32637956
schema:publication	bioRxiv
resource representing a document's body	covid:31326d15d90a07cbd66724dfb0b66120bc04a820#body_text
is schema:about of	named entity 'disease' named entity 'SARS-CoV-2' named entity 'synergy' named entity 'Overall' named entity 'tested' named entity 'SARS-CoV-2' covid:arg/31326d15d90a07cbd66724dfb0b66120bc04a820 named entity 'testing' named entity 'antagonism' named entity 'synergistic' named entity 'worldwide' named entity 'antagonistic' named entity 'result' named entity 'remdesivir' named entity 'mechanisms' named entity 'umifenovir' named entity 'amodiaquine' named entity 'synergistic' named entity 'remdesivir' named entity 'viral disease' named entity 'SARS-CoV-2' named entity 'synergistic' named entity 'SARS-CoV-2' named entity 'emergency use authorization' named entity 'synergistic' named entity 'Synergistic' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'antiviral' named entity 'infection' named entity 'antiviral drugs' named entity 'SARS-CoV-2' named entity 'ATP' named entity 'COVID' named entity 'preclinical research' named entity 'anti-infective' named entity 'acidic pH' named entity 'ATP' named entity 'phosphorylated' named entity '4-aminoquinoline' named entity 'Nitazoxanide' named entity 'hydroxychloroquine' named entity 'opendata' named entity 'viral shedding' named entity 'umifenovir' named entity 'remdesivir' named entity 'hydroxychloroquine' named entity 'Vero E6' named entity 'drug repurposing' named entity 'Umifenovir' named entity 'Interferon' named entity 'prodrug' named entity 'amines' named entity 'Phase III' named entity 'half-life' named entity 'GSK-3β' named entity 'peak concentration' named entity 'hydroxychloroquine' named entity 'virus' named entity 'dose-dependent' named entity 'EUA' named entity 'synergistic' named entity 'mechanisms of action' named entity 'synergistic' named entity 'adverse effects' named entity 'ClinicalTrials.gov' named entity 'RdRp' named entity 'hydroxychloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software